KYTX
KYTX clinical trials: Kyverna Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Kyverna Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 7
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KYTX on the catalyst calendar · KYTX registry changes
- Primary completion Jun 16, 2026ActualPhase 1/Phase 2NCT06400303KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic SclerosisKyverna Therapeutics · Systemic SclerosisTerminatedKYTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2025ActualPhase 1/Phase 2NCT06342960KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisKyverna Therapeutics · Lupus NephritisTerminatedKYTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2026ActualPhase 1/Phase 2NCT05938725KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisKyverna Therapeutics · Lupus NephritisTerminatedKYTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2/Phase 3NCT06193889KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisKyverna Therapeutics · Myasthenia GravisRecruitingKYTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2026ActualPhase 2NCT06588491KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person...Kyverna Therapeutics · Stiff-Person SyndromeCompletedKYTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2041Sponsor estimateNo phase registeredNCT07403188A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101Kyverna Therapeutics · Refractory Lupus NephritisRecruitingKYTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 2NCT06384976KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisKyverna Therapeutics · Multiple Sclerosis, Primary ProgressiveActive, not recruitingKYTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1NCT06152172CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101David Porter · Idiopathic Inflammatory MyopathiesActive, not recruitingKYTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2026ActualPhase 1NCT06451159A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple SclerosisBruce Cree · Progressive Multiple SclerosisActive, not recruitingKYTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT06475495Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisCharite University, Berlin, Germany · Rheumatoid ArthritisActive, not recruitingKYTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT06138132A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple...Stanford University · Multiple SclerosisRecruitingKYTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1/Phase 2NCT06590545Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA VasculitisDavid Simon · ANCA-IgG-positive ANCA Associated VasculitisNot yet recruitingKYTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner